2010, Number 3
<< Back Next >>
Med Int Mex 2010; 26 (3)
Prevalence of hyperhomocysteinemia in a group of patients with diagnosis of type 2 diabetes mellitus at Yucatan, Mexico
Castro SCJ, Lara PDM, Solís RF
Language: Spanish
References: 23
Page: 207-212
PDF size: 163.04 Kb.
ABSTRACT
Background: The cardiovascular diseases are the first cause of mortality in our country. The diabetic patients have increased the risk of cardiovascular disease. The process responsible for the cardiovascular disease involves multiple factors among them the homocysteine. The aim of this study was to determine the prevalence of hyperhomocysteinemia in a group of diabetic patients and to compare with a group of non-diabetic patients.
Methods: A case-control study was made. To each patient lipid profile, glucose, creatinine and homocysteine were determined. The prevalence of hyperhomocysteinemia in each group was determined and the variables associated to hyperhomocysteinemia were determined.
Results: We studied to 98 subjects, 50 diabetic patients and 48 controls paired according to age and gender. The values of homocysteine were majors in the group control that enters the group of diabetic patients (9,8 versus 8,7 μmol/L, p=0.4). The Hhcy was related with the creatinine levels (p=0.01).
Conclusions: The prevalence of hyperhomocysteinemia in the group of diabetics was of 22%. The presence of hyperhomocysteinemia kept correlation with the degree of renal function.
REFERENCES
Cardiovascular Diseases: WHO: http://www.who.int/ncd/cvd/ CardioBroch.pdf 2002.
Murray CJL, López A. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997;347:1498-1504.
Principales causas de mortalidad general 2004. Secretaría de Salud. (http://www.salud.gob.mx/index_2004.html).
Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006;83:456S-460S.
McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
Woodward M, Rumley A, Rumley A, Rumley C, et al. The association between homocysteine and myocardial infarction is independent of age, sex, blood pressure, cholesterol, smoking and markers of inflammation: the Glasgow Myocardial Infarction Study. Blood Coagul Fibrinolysis 2006;17:1-5.
Aksoy M, Basar Y, Salmayenli N, Ayalp K, et al. Hyperhomocysteinemia in patients with arterial occlusive disease. Surg Today 2006;36:327-331.
Giusti B, Marcucci R, Lapini I, et al. Role of hyperhomocysteinemia in aortic disease. Cell Mol Biol 2004;50:945-952.
Celermajer DS, Sorensen K, Ryalls M, et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993;22:854-858.
Van den Berg M, Boers GH, Franken DG, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;25:176-181.
Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res 1993;34:2051-2061.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999;99:178-182.
Russo GT, Di Benedetto A, Giorda C, et al. Correlates of total homocysteine plasma concentration in type 2 diabetes. Eur J Clin Invest 2004;34:197-204.
Essais O, Bouzid C, Ouni Z, et al. Factors influencing homocysteinemia in type 2 diabetes patients. Tunis Med 2006;84:279-281.
Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 2004;140:94-100.
Ndrepepa G, Kastrati A, Braun S, et al. Circulating homocysteine levels in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 2008;18:66-73.
Jacques PF, Rosenberg IH, Rogers G, et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the Third National Health and Nutrition Examination Survey. Am J Clin Nutr 1999;69:482-489.
Brattstrom L, Lindgren A, Israelsson B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994;236:633-641.
Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999;10:891-900.
Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693- 2698.
Volleset SE, Nygard O, Kvale G, et al. The Hordaland Homocysteine Study: lifestyle and total plasma homocysteine in western Norway. In: Graham I, Refsum H, Rosenberg IH, Ueland PM, editors. Homocysteine Metabolism from Basic Science to Clinic Medicine. Norwell, MA: Kluwer Academic Publishers, 1997;pp:177-182.
Pongchaidecha M, Srikusalanukul V, Chattananon A, Tanjariyaporn S. Effect of metformin on plasma homocysteine, vitamin B12 and folic acid: a cross-sectional study in patients with type 2 diabetes mellitus. J Med Assoc Thai 2004;87:780- 787.
Full text